疾病监测与控制2024，Vol.18Issue(5)：413-417,5.DOI:10.19891/j.issn1673-9388.(2024)05-0413-05
免疫检查点抑制剂在宫颈癌中的应用进展
PROGRESS IN THE APPLICATION OF IMMUNE CHECKPOINT INHIBITORS IN CERVICAL CANCER
赵云云 1孙晓革2
作者信息
- 1. 内蒙古医科大学,内蒙古 呼和浩特 010059
- 2. 内蒙古医科大学附属医院 放疗科,内蒙古 呼和浩特 010050
- 折叠
摘要
Abstract
Cervical cancer is one of the most common malignant tumors,which seriously threatens the life and health of women in our country.Most patients are in the middle and late stages of their first visit and lose the opportunity for surgery.Concur-rent chemoradiotherapy is the standard treatment for locally advanced cervical cancer,but about 15％of patients still have recur-rence or metastasis after treatment.Once metastasis occurs,the follow-up treatment is very limited.Immunotherapy,represented by various immune checkpoint inhibitors,has achieved good efficacy in recent years and has become a first-line drug in many cancer species.In order to improve the efficacy of cervical cancer and explore the effectiveness and safety of immunotherapy in cervical cancer,a number of clinical studies have been conducted at home and abroad.Currently,the commonly used immune checkpoints include cytotoxic T lymphocyt-associated antigen 4(CTLA4),programmed death receptor 1(PD-1)and ligand 1(PD-L1)[1].This article reviews the clinical application of immune checkpoint inhibitors in local advanced cervical cancerand recurrent cervical cancer,and introduces immunotherapy related markers.关键词
PD-1/PD-L1/CTLA-4/双抗联合/宫颈癌/标志物Key words
PD-1/PD-L1/CTLA-4/combination of two antibodies/cervical cancer/marker分类
医药卫生引用本文复制引用
赵云云,孙晓革..免疫检查点抑制剂在宫颈癌中的应用进展[J].疾病监测与控制,2024,18(5):413-417,5.
